PathAI has launched the AIM-IHC Breast Panel, a cutting-edge AI-powered tool designed to revolutionize breast cancer diagnostics by accurately quantifying key biomarkers such as HER2, ER, PR, and Ki-67. This innovation, available on the AISight® Image Management System (IMS), addresses the critical need for standardized and reliable methods in pathology, enhancing the precision of breast cancer assessments.
The AIM-IHC Breast Panel's ability to perform automated tissue segmentation and detect on-slide controls represents a leap forward in diagnostic technology. It differentiates between invasive and non-invasive cancer areas, providing overlays that aid in algorithmic scoring. This feature is tailored to improve pathologist workflows by enhancing the identification of regions of interest and the accuracy of invasive cancer segmentation.
Traditional methods of biomarker quantification, especially for Ki-67, have been notably labor-intensive. The AIM-IHC Breast Panel mitigates this by automating the classification of invasive cancer and generating percentage-based results for positive cancer cells. This automation not only saves time but also increases the reliability of the scoring process, enabling pathologists to make more informed decisions.
Andrew Beck, CEO of PathAI, highlighted the company's dedication to advancing precision pathology through AI technology. The AIM-IHC Breast Panel is part of PathAI's broader suite of AI-powered solutions on the AISight® IMS, which aims to centralize pathology workflows and integrate various AI-driven tools for labs. This unified approach is designed to boost efficiency and precision in pathology practices.
The potential impact of the AIM-IHC Breast Panel extends to improving the overall quality of breast cancer diagnostics and research. By ensuring more accurate and consistent biomarker quantification, the tool could lead to better treatment decisions and outcomes for patients. Currently, the technology is available for research use in the U.S. and has received CE-IVD marking in Europe, the UK, and Switzerland, indicating its compliance with in vitro diagnostic medical device regulations.
PathAI's advancements in AI-powered pathology solutions, including the AIM-IHC Breast Panel, are setting the stage for a transformative shift in the field. These innovations promise to streamline diagnostic processes, reduce manual workload, and allow pathologists to dedicate more attention to complex cases, ultimately enhancing patient care.
